Status:
ENROLLING_BY_INVITATION
Population Health Approach to Optimizing Medications in Older Adults
Lead Sponsor:
Cedars-Sinai Medical Center
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Medication Adverse Effects
Older Adults (65 Years and Older)
Eligibility:
All Genders
65+ years
Phase:
NA
Brief Summary
This randomized controlled pragmatic pilot study examines the feasibility and acceptability of a population health-based deprescribing intervention that leverages a polypharmacy risk prediction model....
Detailed Description
This pilot clinical trial will examine the feasibility and acceptability of a medication management intervention that uses risk stratification to identify older adults (including older adults with Mil...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients will be invited to enroll in the study if they are in the top decile of risk selected by a risk prediction model of polypharmacy-related adverse events. The risk prediction model includes variables such as: age, sex, recent healthcare encounters, current and past medications, current and past lab tests, current and past diagnoses.
- 65 years of age or older
- Have a primary care clinician within the Cedars-Sinai Health System who uses MyCSLink (electronic health record used by Cedars-Sinai).
- Part of a Cedars-Sinai Health System population health registry (e.g., enrolled in an Accountable Care Organization, Medicare Advantage plan, or Primary Care First program)
- Diagnosis of Mild Cognitive Impairment or Dementia at baseline (for one intervention group) on the problem list
- Exclusion criteria include:
- Patients for whom there is an active substance use disorder (defined by a physician) and thus for whom the intervention may not be appropriate
- Patients with an organ transplant
- Visits with a Cedars-Sinai Medical Center pharmacist for a polypharmacy consult within the last 6 months
- Patients who previously indicated in the EHR that they wish to opt out of participating in research studies.
- Patients enrolled in CS360, a program for highly complex medical patients, who already receive polypharmacy services.
Exclusion
Key Trial Info
Start Date :
May 19 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06110156
Start Date
May 19 2025
End Date
December 1 2026
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048